- ►drclaudiaanrig.com [PDF] RH Eckel, SM Grundy, PZ Zimmet - The Lancet, 2005 - Elsevier The metabolic syndrome is a common metabolic disorder that results from the
increasing prevalence of obesity. The disorder is defined in various ways, but
in the near future a new definition(s) will be applicable worldwide. The ... Cited by 1555 - Related articles - All 41 versions
G Marchesini, R Marzocchi, F Agostini, E … - Current opinion in lipidology, 2005 - journals.lww.com Purpose of review Clinical, epidemiological and biochemical data strongly
support the concept that nonalcoholic fatty liver disease is the hepatic
manifestation of the metabolic syndrome. Insulin resistance is the common ... Cited by 155 - Related articles - BL Direct - All 6 versions
G Targher, L Bertolini, R Padovani, S Rodella, … - Diabetes Care, 2007 - Am Diabetes Assoc RESULTS—The unadjusted prevalence of NAFLD was 69.5% among participants, and
NAFLD was the most common cause (81.5%) of hepatic steatosis on ultrasound
examination. The prevalence of NAFLD increased with age (65.4% among ... Cited by 79 - Related articles - BL Direct - All 8 versions
- ►ajcn.org AM Zivkovic, JB German, AJ Sanyal - American Journal of Clinical Nutrition, 2007 - Am Soc Nutrition Nonalcoholic fatty liver disease (NAFLD) is a significant health problem and
affects 70 million adults in the United States (30% of the adult population),
and an estimated 20% of these individuals have the most severe form of ... Cited by 57 - Related articles - BL Direct - All 7 versions
G Targher, L Bertolini, L Scala, G Zoppini, L … - Diabetic medicine, 2005 - pt.wkhealth.com Results: Plasma hs-CRP, fibrinogen, v-WF and plasminogen activator inhibitor-1
(PAI-1) activity levels were markedly higher (P < 0.01 or less) in subjects with
non-alcoholic HS (n = 35) than in those without HS (n = 65). The former ... Cited by 54 - Related articles - BL Direct - All 5 versions
E Gomez-Dominguez, JP Gisbert, JA Moreno- … - Alimentary Pharmacology and Therapeutics, 2006 - medscape.com Currently, there are no proven effective therapies available for the treatment
of NAFLD and strategies have mainly led to treat or control underlying risk
factors. [1-4, 7, 11, 14] Promising pharmacological treatments have been ... Cited by 52 - Related articles - BL Direct - All 11 versions
MR Charlton, PJ Pockros, SA Harrison… - Hepatology, 2006 - interscience.wiley.com Obesity and the metabolic syndrome have hepatic manifestations, including
steatosis and progression of fibrosis. In individuals with chronic hepatitis C,
obesity is associated with inflammation, insulin resistance, steatosis, ... Cited by 49 - Related articles - BL Direct - All 3 versions
- ►adisonline.com [PDF] J Medina, R Moreno-Otero - Drugs, 2005 - ingentaconnect.com Oxidative stress is a common pathogenetic mechanism contributing to initia-
Abstract tion and progression of hepatic damage in a variety of liver disorders.
Cell damage occurs when there is an excess of reactive species derived from ... Cited by 42 - Related articles - BL Direct - All 6 versions
P Loria, A Lonardo, N Carulli - Dig Dis, 2005 - content.karger.com Background:None of the synonyms of nonalcoholic fatty liver disease (NAFLD)
include clinical correlates nor do they mention insulin resistance, a recognized
determinant of the etiopathogenesis and natural history of NAFLD. Method: ... Cited by 30 - Related articles - All 6 versions
